SCHEMBL4138583

SCHEMBL4138583

COc1cccc(-c2nc(C)c(-c3ccccc3)c(=O)n2CCc2ccccc2)c1F

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CASR P41180 17/20 0.56
NR1I2 O75469 5/20 0.56
TP53 P04637 1/20 0.46
GNRHR P30968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135141 0.88 CASR (0.53) CASRNR1I2TP53GNRHR
SCHEMBL4142918 0.85 CASR (0.64) CASRNR1I2
SCHEMBL4143693 0.84 CASR (0.55) CASRNR1I2TP53GNRHR
SCHEMBL4138848 0.83 CASR (0.66) CASRNR1I2GNRHR
SCHEMBL4140230 0.82 TP53 (0.49) CASRNR1I2TP53
SCHEMBL4143317 0.81 CASR (0.81) CASRNR1I2
SCHEMBL4143352 0.81 CASR (0.64) CASRNR1I2TP53GNRHR
SCHEMBL5027057 0.80 CASR (0.56) CASRNR1I2
SCHEMBL4153000 0.79 CASR (0.66) CASRNR1I2
SCHEMBL4148803 0.79 CASR (0.78) CASRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB CASR 12/4885NR1I2 3373/4885TP53 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.